Results 121 to 130 of about 75,341 (263)

Impact of schizophrenia on anterior and posterior hippocampus during memory for complex scenes. [PDF]

, 2017
ObjectivesHippocampal dysfunction has been proposed as a mechanism for memory deficits in schizophrenia. Available evidence suggests that the anterior and posterior hippocampus could be differentially affected.
Carter, CS, Hannula, DE, Layher, E, Lesh, TA, Niendam, TA, Ragland, JD, Ranganath, C, Solomon, M   +7 more
core   +2 more sources

Perphenazine in Treatment-Resistant Schizophrenia

Cureus
Antipsychotics are considered a gold standard treatment for schizophrenia. However, there is considerable variation in antipsychotic medication choice. Factors considered involved include symptomatology, prior response, and adverse reactions. This case report presents a 38-year-old male patient with schizophrenia in acute psychosis refractory to ...
Hower, Michael R, Karlapati, Surya Kumar, Bachu, Anil K   +2 more
openaire   +2 more sources

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Efficacy of modified electroconvulsive therapy as augmentation agent in treatment-resistant schizophrenia

Indian Journal of Health Sciences and Biomedical Research KLEU
AIM: The aim of the study was to study the efficacy of modified electroconvulsive therapy (MECT) as an augmentation agent in schizophrenia, with particular emphasis in treatment-resistant schizophrenia.
Chitrakshee Singh, Sudhir Kumar, Abhinav Pandey, Paramvir Singh   +3 more
doaj   +1 more source

Prescribing trends in treatment-resistant schizophrenia

Psychiatry and Clinical Psychopharmacology, 2017
Objectives: Schizophrenia is a common mental health condition associated with significant morbidity and excess early mortality. Treatment-resistant schizophrenia (TRS) occurs in about one in three patients diagnosed with schizophrenia.
Aynur Görmez, Ayşe Kurtulmuş, Can Tuncer, Serhat Çıtak   +3 more
doaj   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Treatment resistance in Schizophrenia

European Psychiatry, 2011
DiagnosisThe diagnosis of treatment resistant schizophrenia generally follows two not always consistent lines of thinking: one is based on research strategies, the other one on every day clinical practice. Both require a failure to respond to at least two (sometimes three) treatment attempts of adequate duration with an adequate dose of an ...
openaire   +1 more source

“All that I've been through has made me who I am”: youth conceptualisations of personal recovery in mental health

Child and Adolescent Mental Health, EarlyView.
Background Youth is a transitional period from 15 to 24 years involving developmental milestones that may be adversely affected by mental health (MH) concerns. Clinical interventions tend to focus on the reduction or cure of illness‐based psychiatric symptoms.
Linda Anderson, Vicki C. Dallinger, Govind Krishnamoorthy, Carol du Plessis, Arun Pillai‐Sasidharan, Alice Ayres, Lillian Waters, Yasmin Groom, Bronwyn Rees, Mike Slade, Jessica Gildersleeve, Lorelle Burton, Renee Ireland   +12 more
wiley   +1 more source

Distinguishing Between Treatment-Resistant and Non-Treatment-Resistant Schizophrenia Using Regional Homogeneity

Frontiers in Psychiatry, 2018
Background: Patients with treatment-resistant schizophrenia (TRS) and non-treatment-resistant schizophrenia (NTRS) respond to antipsychotic drugs differently. Previous studies demonstrated that patients with TRS or NTRS exhibited abnormal neural activity
Shuzhan Gao, Shuzhan Gao, Shuiping Lu, Shuiping Lu, Xiaomeng Shi, Xiaomeng Shi, Yidan Ming, Yidan Ming, Chaoyong Xiao, Jing Sun, Jing Sun, Hui Yao, Hui Yao, Xijia Xu, Xijia Xu   +14 more
doaj   +1 more source